Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Drug Action01:24

Principles of Drug Action

7.2K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
7.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.2K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

49
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
49
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

28
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
28
Prodrugs01:30

Prodrugs

3.4K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.4K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

6.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrids/Conjugates/Chimera Drugs-Antimicrobial Hybrids: Antibiotics, Antifungals, Antituberculars, Antimalarials.

Current medicinal chemistry·2025
Same author

Hybrid/Chimera Drugs - Part 1 - Drug Hybrids Affecting Diseases of the Central Nervous System.

Current medicinal chemistry·2024
Same author

Mutual Prodrugs - Codrugs.

Current medicinal chemistry·2022
Same author

Synthesis and preliminary biological evaluation of gabactyzine, a benactyzine-GABA mutual prodrug, as an organophosphate antidote.

Scientific reports·2022
Same author

An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.

Cancer chemotherapy and pharmacology·2022
Same author

Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer.

Pharmaceuticals (Basel, Switzerland)·2021

Related Experiment Video

Updated: Oct 25, 2025

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

8.0K

Dimeric Drugs.

Abraham Nudelman1

  • 1Chemistry Department, Bar Ilan University, Ramat Gan 52900, Israel.

Current Medicinal Chemistry
|August 10, 2021
PubMed
Summary
This summary is machine-generated.

This review explores symmetrical-dimeric drugs, highlighting their diverse structures and applications in treating cancer, infections, and other conditions. While dimeric drugs show promise, predicting their enhanced activity over monomers remains challenging.

Keywords:
Monomeric drugsbiological activitydimeric drugsindustrial medicinal chemistssymmetry linking bridgessynergy

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.0K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K

Related Experiment Videos

Last Updated: Oct 25, 2025

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library
10:17

Creating Highly Specific Chemically Induced Protein Dimerization Systems by Stepwise Phage Selection of a Combinatorial Single-Domain Antibody Library

Published on: January 14, 2020

8.0K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.0K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K

Area of Science:

  • Medicinal Chemistry
  • Drug Discovery
  • Pharmacology

Background:

  • Symmetrical-dimeric drugs, composed of two identical monomers linked by a bridge, represent a versatile class of biologically active compounds.
  • These dimeric structures are found in various therapeutic areas, including anticancer, antimicrobial, and antiviral agents, as well as treatments for diabetes, inflammation, and neurological disorders.

Purpose of the Study:

  • To review and summarize the structural diversity of symmetrical-dimeric drugs.
  • To emphasize the broad range of biological activities exhibited by these dimeric compounds.
  • To discuss potential reasons for the enhanced activity of dimeric drugs compared to their monomeric counterparts.

Main Methods:

  • Comprehensive literature review of symmetrical-dimeric drugs.
  • Analysis of reported structures and biological activities.
  • Discussion of proposed mechanisms for enhanced dimeric drug efficacy.

Main Results:

  • An extensive array of symmetrical-dimeric drugs across multiple therapeutic categories was identified.
  • The review highlights the versatility and potential of dimeric structures in drug design.
  • Limited studies directly compare the potency of dimeric drugs to their monomers, with few hypotheses offered for observed activity differences.

Conclusions:

  • Symmetrical-dimeric drugs offer a wide spectrum of therapeutic potential, particularly in oncology and infectious diseases.
  • Further research is needed to elucidate the structure-activity relationships and predictive models for dimeric drug development.
  • The findings are expected to stimulate interest among medicinal chemists in both academic and industrial settings for novel dimeric drug design.